

CURRICULUM VITAE

Name: Pattranuch Chusri
Date of birth: December 7, 1985
Gender: Female
Nationality: Thai
Home address: 36/1 M.4, T.Papai, A.Sansai
Chiang Mai, 50210 Thailand
Tel. 66-91-8582707
E-mail address: pattranuch.chu@mfu.ac.th

Current position

- **Lecturer** since October 2015
- **Work address** School of Medicine, Mae Fah Luang University
Chiang Rai, 57100 Thailand
Tel. 66-53-916566 Fax. 66-53-916570
- **Area of academic expertise** Medical microbiology
Medical virology
Molecular biology
- **Assigned courses** Principles of medical microbiology and parasitology
Applied immunology and infectious disease
Hematologic and immune system
Biochemistry and molecular biology

Educational Background

- **Ph.D., Microbiology**, Chiang Mai University, Thailand, 2014
Thesis Title: Molecular Mechanisms of Interferon Resistance Mediated by NS3, NS4A and NS4B Genes of Hepatitis C Viruses in Chronic Hepatitis C Patients Treated with Peginterferon- α and Ribavirin

- **B.Sc., Medical Technology**, Chiang Mai University, Thailand, 2008
Thesis Title: Optimization of *Legionella pneumophila* DNA extraction for PCR

Scholarship

Royal Golden Jubilee Ph.D. Program, Thailand Research Fund, 2008-2014

Work Experience

- **Research Assistant**, Liver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, US, 2011-2013
- **Research Assistant**, Department of Infection Control and Prevention, Kurume University School of Medicine, JAPAN, April 2015-June 2015

Publications

1. **Chusri P**, Kumthip K, Hong J, Zhu C, Jilg N, Fusco DN, Brisac C, Schaefer EA, Cai D, Peng LF, Maneekarn N, Lin W, Chung RT (2016), HCV induces transforming growth factor β 1 through activation of endoplasmic reticulum stress and the unfolded protein response. *Sci Rep.* 2016; 6:22487
2. Zhu C, Xiao F, Hong J, Wang K, Liu X, Cai D, Fusco DN, Zhao L, Jeong SW, Brisac C, **Chusri P**, Schaefer EA, Zhao H, Peng LF, Lin W, Chung RT (2015), EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway. *J Virol.* 2015; 89:6608-18
3. **Chusri P**, Kumthip K, Pantip C, Thongsawat S, O'Brien A, Maneekarn N. Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy. *Virus Res.* 2015; 196:37-43
4. Kumthip K, **Chusri P**, Pantip C, Thongsawat S, O'Brien A, Nelson KE, Maneekarn N. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy. *J Med Virol.* 2014; 86:1360-5
5. Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, Goto K, Brisac C, **Chusri P**, Fusco DN, Chevaliez S, Luther J, Kumthip K, Urban TJ, Peng LF, Lauer GM, Chung RT. Kinetic differences in the induction of interferon stimulated genes by interferon- α and interleukin 28B are altered by infection with hepatitis C virus. *Hepatology.* 2014; 59:1250-61

6. Kumthip K, **Chusri P**, Jilg N, Zhao L, Fusco DN, Zhao H, Goto K, Cheng D, Schaefer EA, Zhang L, Pantip C, Thongsawat S, O'Brien A, Peng LF, Maneekarn N, Chung RT, Lin W. HCV NS5A disrupts STAT1 phosphorylation and suppresses type I IFN signaling. *J Virol*. 2012; 86:8581-91
7. Kumthip K, **Pantip C**, Chusri P, Thongsawat S, O'Brien A, Nelson KE, Maneekarn N. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. *J Virol Hepat*. 2011; 18:e117-25
8. Khamrin P, Thongprachum A, Chaimongkol N, **Chusri P**, Okitsu S, Ushijima H, Maneekarn N. Evolutionary consequences of G9 rotaviruses circulating in Thailand. *Infect Genet Evol*. 2009; 9:1394-9

Conference presentations

1. Impact of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b, and 6f on the response to pegylated interferon and ribavirin combination therapy. The 21st International Symposium on Hepatitis C Virus and Related Viruses, Banff, Alberta, Canada, September 7-11, 2014
2. Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1, 3, and 6 on the response to pegylated interferon and ribavirin therapy. The RGJ-Ph.D. Congress XV, Pattaya, Chonburi, Thailand, May 28-30, 2014
3. HCV induces hepatocyte TGF- β 1 release through activation of ER stress and the unfolded protein response. The 63th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012), Boston, MA, USA, November 9-13, 2012